|
GB835638A
(en)
|
1956-12-01 |
1960-05-25 |
Novo Terapeutisk Labor As |
Insulin crystal suspensions having a protracted effect
|
|
GB840870A
(en)
|
1957-08-03 |
1960-07-13 |
Novo Terapeutisk Labor As |
Improvements in or relating to insulin preparations
|
|
US3868358A
(en)
|
1971-04-30 |
1975-02-25 |
Lilly Co Eli |
Protamine-insulin product
|
|
US3758683A
(en)
|
1971-04-30 |
1973-09-11 |
R Jackson |
Insulin product
|
|
GB1554157A
(en)
|
1975-06-13 |
1979-10-17 |
Takeda Chemical Industries Ltd |
Stable insulin preparation for intra nasal administration
|
|
US4153689A
(en)
|
1975-06-13 |
1979-05-08 |
Takeda Chemical Industries, Ltd. |
Stable insulin preparation for nasal administration
|
|
GB1527605A
(en)
|
1975-08-20 |
1978-10-04 |
Takeda Chemical Industries Ltd |
Insulin preparation for intranasal administration
|
|
JPS6033474B2
(ja)
|
1978-05-11 |
1985-08-02 |
藤沢薬品工業株式会社 |
新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
|
|
US4783441A
(en)
|
1979-04-30 |
1988-11-08 |
Hoechst Aktiengesellschaft |
Aqueous protein solutions stable to denaturation
|
|
DE3064888D1
(en)
|
1979-04-30 |
1983-10-27 |
Hoechst Ag |
Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
|
|
JPS55153712A
(en)
|
1979-05-18 |
1980-11-29 |
Kao Corp |
Insulin pharmaceutical preparation and its production
|
|
DE3033127A1
(de)
|
1980-09-03 |
1982-04-08 |
Hoechst Ag, 6000 Frankfurt |
Neue analoga des insulins
|
|
US4367737A
(en)
|
1981-04-06 |
1983-01-11 |
George Kozam |
Multiple barrel syringe
|
|
EP0083619A1
(en)
|
1981-07-17 |
1983-07-20 |
Nordisk Insulinlaboratorium |
A stable aqueous, therapeutic insulin preparation and a process for preparing it
|
|
NL193099C
(nl)
|
1981-10-30 |
1998-11-03 |
Novo Industri As |
Gestabiliseerde insuline-oplossing.
|
|
DE3326472A1
(de)
|
1983-07-22 |
1985-02-14 |
Hoechst Ag, 6230 Frankfurt |
Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
|
|
DE3326473A1
(de)
|
1983-07-22 |
1985-01-31 |
Hoechst Ag, 6230 Frankfurt |
Pharmazeutisches mittel zur behandlung des diabetes mellitus
|
|
DE3327709A1
(de)
|
1983-07-29 |
1985-02-07 |
Hoechst Ag, 6230 Frankfurt |
Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
|
|
DE3333640A1
(de)
|
1983-09-17 |
1985-04-25 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
|
|
US4839341A
(en)
|
1984-05-29 |
1989-06-13 |
Eli Lilly And Company |
Stabilized insulin formulations
|
|
CA1244347A
(en)
|
1984-05-29 |
1988-11-08 |
Eddie H. Massey |
Stabilized insulin formulations
|
|
ATE50502T1
(de)
|
1984-06-09 |
1990-03-15 |
Hoechst Ag |
Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
|
|
DE3440988A1
(de)
|
1984-11-09 |
1986-07-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
|
|
DK113585D0
(da)
|
1985-03-12 |
1985-03-12 |
Novo Industri As |
Nye peptider
|
|
US5008241A
(en)
|
1985-03-12 |
1991-04-16 |
Novo Nordisk A/S |
Novel insulin peptides
|
|
DK347086D0
(da)
|
1986-07-21 |
1986-07-21 |
Novo Industri As |
Novel peptides
|
|
IL78425A
(en)
|
1985-04-15 |
1991-05-12 |
Lilly Co Eli |
Intranasal formulation containing insulin
|
|
US4689042A
(en)
|
1985-05-20 |
1987-08-25 |
Survival Technology, Inc. |
Automatic medicament ingredient mixing and injecting apparatus
|
|
DE3526995A1
(de)
|
1985-07-27 |
1987-02-05 |
Hoechst Ag |
Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
|
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
|
US4960702A
(en)
|
1985-09-06 |
1990-10-02 |
Codon |
Methods for recovery of tissue plasminogen activator
|
|
DE3541856A1
(de)
|
1985-11-27 |
1987-06-04 |
Hoechst Ag |
Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
|
|
DE3636903A1
(de)
|
1985-12-21 |
1987-07-02 |
Hoechst Ag |
Fusionsproteine mit eukaryotischem ballastanteil
|
|
US5496924A
(en)
|
1985-11-27 |
1996-03-05 |
Hoechst Aktiengesellschaft |
Fusion protein comprising an interleukin-2 fragment ballast portion
|
|
CA1275922C
(en)
|
1985-11-28 |
1990-11-06 |
Harunobu Amagase |
Treatment of cancer
|
|
DE3544295A1
(de)
|
1985-12-14 |
1987-06-19 |
Bayer Ag |
Thermoplastische formmassen mit hoher kriechstromfestigkeit
|
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
|
PH23446A
(en)
|
1986-10-20 |
1989-08-07 |
Novo Industri As |
Peptide preparations
|
|
IE62879B1
(en)
|
1987-02-25 |
1995-03-08 |
Novo Nordisk As |
Novel insulin derivatives
|
|
US5034415A
(en)
|
1987-08-07 |
1991-07-23 |
Century Laboratories, Inc. |
Treatment of diabetes mellitus
|
|
DE3726655A1
(de)
|
1987-08-11 |
1989-02-23 |
Hoechst Ag |
Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
|
|
DK257988D0
(da)
|
1988-05-11 |
1988-05-11 |
Novo Industri As |
Nye peptider
|
|
US6875589B1
(en)
|
1988-06-23 |
2005-04-05 |
Hoechst Aktiengesellschaft |
Mini-proinsulin, its preparation and use
|
|
DE3827533A1
(de)
|
1988-08-13 |
1990-02-15 |
Hoechst Ag |
Pharmazeutische zubereitung zur behandlung des diabetes mellitus
|
|
US4923162A
(en)
|
1988-09-19 |
1990-05-08 |
Fleming Matthew C |
Radiation shield swivel mount
|
|
DE3837825A1
(de)
|
1988-11-08 |
1990-05-10 |
Hoechst Ag |
Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
|
|
US5225323A
(en)
|
1988-11-21 |
1993-07-06 |
Baylor College Of Medicine |
Human high-affinity neurotransmitter uptake system
|
|
HUT56857A
(en)
|
1988-12-23 |
1991-10-28 |
Novo Nordisk As |
Human insulin analogues
|
|
US4994439A
(en)
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
|
IL93282A
(en)
|
1989-02-09 |
1995-08-31 |
Lilly Co Eli |
Insulin analogues
|
|
US5514646A
(en)
|
1989-02-09 |
1996-05-07 |
Chance; Ronald E. |
Insulin analogs modified at position 29 of the B chain
|
|
DK134189D0
(da)
|
1989-03-20 |
1989-03-20 |
Nordisk Gentofte |
Insulinforbindelser
|
|
DK0471036T4
(da)
|
1989-05-04 |
2004-07-19 |
Southern Res Inst |
Indkapslingsfremgangsmåde
|
|
GR1005153B
(el)
|
1989-08-29 |
2006-03-13 |
The General Hospital Corporation |
Πρωτεινες συντηξεως, παρασκευη τους και χρηση τους.
|
|
US5227293A
(en)
|
1989-08-29 |
1993-07-13 |
The General Hospital Corporation |
Fusion proteins, their preparation and use
|
|
US5358857A
(en)
|
1989-08-29 |
1994-10-25 |
The General Hospital Corp. |
Method of preparing fusion proteins
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
|
US5397771A
(en)
|
1990-05-10 |
1995-03-14 |
Bechgaard International Research And Development A/S |
Pharmaceutical preparation
|
|
ATE164080T1
(de)
|
1990-05-10 |
1998-04-15 |
Bechgaard Int Res |
Pharmazeutische zubereitung enthaltend n- glykofurole und n-äthylenglykole
|
|
DK155690D0
(da)
|
1990-06-28 |
1990-06-28 |
Novo Nordisk As |
Nye peptider
|
|
DK10191D0
(da)
|
1991-01-22 |
1991-01-22 |
Novo Nordisk As |
Hidtil ukendte peptider
|
|
US5272135A
(en)
|
1991-03-01 |
1993-12-21 |
Chiron Ophthalmics, Inc. |
Method for the stabilization of methionine-containing polypeptides
|
|
CA2038597A1
(en)
|
1991-03-19 |
1992-09-20 |
Jose P. Garzaran |
A method and a pharmaceutical preparation for treating pain
|
|
US6468959B1
(en)
|
1991-12-05 |
2002-10-22 |
Alfatec-Pharm Gmbh |
Peroral dosage form for peptide containing medicaments, in particular insulin
|
|
US5614219A
(en)
|
1991-12-05 |
1997-03-25 |
Alfatec-Pharma Gmbh |
Oral administration form for peptide pharmaceutical substances, in particular insulin
|
|
CH682806A5
(de)
|
1992-02-21 |
1993-11-30 |
Medimpex Ets |
Injektionsgerät.
|
|
CH682805A5
(de)
|
1992-02-24 |
1993-11-30 |
Medimpex Ets |
Anzeigeeinrichtung für ein Injektionsgerät.
|
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
US5253785A
(en)
|
1992-04-02 |
1993-10-19 |
Habley Medical Technology Corp. |
Variable proportion dispenser
|
|
ATE148710T1
(de)
|
1992-12-02 |
1997-02-15 |
Hoechst Ag |
Verfahren zur gewinnung von proinsulin mit korrekt verbundenen cystinbrücken
|
|
FI953001A7
(fi)
|
1992-12-18 |
1995-06-16 |
Lilly Co Eli |
Insuliinianalogeja
|
|
US5358708A
(en)
|
1993-01-29 |
1994-10-25 |
Schering Corporation |
Stabilization of protein formulations
|
|
US5478323A
(en)
|
1993-04-02 |
1995-12-26 |
Eli Lilly And Company |
Manifold for injection apparatus
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
JP2837956B2
(ja)
|
1993-06-21 |
1998-12-16 |
ノボ ノルディスク アクティーゼルスカブ |
Ａｓｐ▲上Ｂ２８▼インスリン結晶
|
|
US5506203C1
(en)
|
1993-06-24 |
2001-02-06 |
Astra Ab |
Systemic administration of a therapeutic preparation
|
|
US5534488A
(en)
|
1993-08-13 |
1996-07-09 |
Eli Lilly And Company |
Insulin formulation
|
|
EP2283821A1
(en)
|
1993-11-19 |
2011-02-16 |
Alkermes, Inc. |
Preparation of biodegradable microparticles containing a biologically active agent
|
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
IT1265271B1
(it)
|
1993-12-14 |
1996-10-31 |
Alcatel Italia |
Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
DE4405179A1
(de)
|
1994-02-18 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
|
|
DE4405388A1
(de)
|
1994-02-19 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
|
|
ATE416755T1
(de)
|
1994-03-07 |
2008-12-15 |
Nektar Therapeutics |
Verfahren und zusammensetzung für die pulmonale darreichung von insulin
|
|
US5474978A
(en)
|
1994-06-16 |
1995-12-12 |
Eli Lilly And Company |
Insulin analog formulations
|
|
US5559094A
(en)
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
|
PT779806E
(pt)
|
1994-09-09 |
2001-02-28 |
Takeda Chemical Industries Ltd |
Preparacao de libertacao sustentada contendo um sal metalico de um peptido
|
|
US5879584A
(en)
|
1994-09-10 |
1999-03-09 |
The Procter & Gamble Company |
Process for manufacturing aqueous compositions comprising peracids
|
|
US5547929A
(en)
|
1994-09-12 |
1996-08-20 |
Eli Lilly And Company |
Insulin analog formulations
|
|
US5707641A
(en)
|
1994-10-13 |
1998-01-13 |
Pharmaderm Research & Development Ltd. |
Formulations comprising therapeutically-active proteins or polypeptides
|
|
YU18596A
(sh)
|
1995-03-31 |
1998-07-10 |
Eli Lilly And Company |
Analogne formulacije monomernog insulina
|
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
EP0741188A3
(en)
|
1995-05-05 |
1999-07-14 |
Eli Lilly And Company |
Single chain insulin with high bioactivity
|
|
US5824638A
(en)
|
1995-05-22 |
1998-10-20 |
Shire Laboratories, Inc. |
Oral insulin delivery
|
|
US6143718A
(en)
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
|
EP0831922A2
(en)
|
1995-06-08 |
1998-04-01 |
Therexsys Limited |
Improved pharmaceutical compositions for gene therapy
|
|
AU6242096A
(en)
|
1995-06-27 |
1997-01-30 |
Takeda Chemical Industries Ltd. |
Method of producing sustained-release preparation
|
|
JPH11292787A
(ja)
|
1995-08-15 |
1999-10-26 |
Asahi Chem Ind Co Ltd |
生理活性ペプチドを含有する経粘膜投与製剤
|
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
|
DE19637230A1
(de)
|
1996-09-13 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
|
WO1997046584A1
(de)
|
1996-06-05 |
1997-12-11 |
Boehringer Mannheim Gmbh |
Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
|
|
BR9709845B1
(pt)
|
1996-06-20 |
2008-11-18 |
|
preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
|
|
EP0910402B1
(en)
|
1996-06-20 |
2007-08-08 |
Novo Nordisk A/S |
Insulin preparations containing mannitol
|
|
US5948751A
(en)
|
1996-06-20 |
1999-09-07 |
Novo Nordisk A/S |
X14-mannitol
|
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
|
ATE493998T1
(de)
|
1996-08-08 |
2011-01-15 |
Amylin Pharmaceuticals Inc |
Pharmazeutische zusammensetzung mit einem exendin-4-peptid
|
|
US5783556A
(en)
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
|
US6384016B1
(en)
|
1998-03-13 |
2002-05-07 |
Novo Nordisk A/S |
Stabilized aqueous peptide solutions
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
IL128332A0
(en)
|
1996-08-30 |
2000-01-31 |
Novo Nordisk As |
GLP-1 derivatives
|
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
DE122007000044I2
(de)
|
1997-01-07 |
2011-05-05 |
Amylin Pharmaceuticals Inc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
WO1998035033A1
(en)
|
1997-02-05 |
1998-08-13 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
|
US6043214A
(en)
|
1997-03-20 |
2000-03-28 |
Novo Nordisk A/S |
Method for producing powder formulation comprising an insulin
|
|
EP1005490B1
(en)
|
1997-03-20 |
2006-03-29 |
Novo Nordisk A/S |
Zinc free insulin crystals for use in pulmonary compositions
|
|
US6310038B1
(en)
|
1997-03-20 |
2001-10-30 |
Novo Nordisk A/S |
Pulmonary insulin crystals
|
|
AR012894A1
(es)
|
1997-06-13 |
2000-11-22 |
Lilly Co Eli |
Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
|
|
CA2635352C
(en)
|
1997-06-13 |
2012-09-11 |
Genentech, Inc. |
Stabilized antibody formulation
|
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
|
ES2293688T5
(es)
|
1997-08-08 |
2011-05-04 |
Amylin Pharmaceuticals, Inc. |
Nuevos compuestos análogos de la exendina.
|
|
DE19735711C2
(de)
|
1997-08-18 |
2001-04-26 |
Aventis Pharma Gmbh |
Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
|
|
JP2001521006A
(ja)
|
1997-10-24 |
2001-11-06 |
イーライ・リリー・アンド・カンパニー |
不溶性インシュリン組成物
|
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
|
ZA989744B
(en)
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
|
ES2230727T3
(es)
|
1997-11-12 |
2005-05-01 |
Alza Corporation |
Procedimiento de administracion dermal de polipeptidos.
|
|
ATE383867T1
(de)
|
1997-11-14 |
2008-02-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
|
MXPA00004670A
(es)
|
1997-11-14 |
2003-07-14 |
Amylin Pharmaceuticals Inc |
Compuestos agonistas de exendina novedosos.
|
|
EP1049486A4
(en)
|
1997-12-05 |
2006-01-04 |
Lilly Co Eli |
GLP-1 FORMULATIONS
|
|
WO1999034821A1
(en)
|
1998-01-09 |
1999-07-15 |
Novo Nordisk A/S |
Stabilised insulin compositions
|
|
EP1054594B1
(en)
|
1998-02-13 |
2007-07-04 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and glp-1
|
|
WO1999042482A1
(en)
|
1998-02-23 |
1999-08-26 |
Neurocrine Biosciences, Inc. |
Methods for treatment of diabetes using peptide analogues of insulin
|
|
JP2003522099A
(ja)
|
1998-02-27 |
2003-07-22 |
ノボ ノルディスク アクティーゼルスカブ |
遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
|
|
NZ506839A
(en)
|
1998-03-09 |
2003-05-30 |
Zealand Pharma As |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
ATE413889T1
(de)
|
1998-06-05 |
2008-11-15 |
Nutrinia Ltd |
Insulin angereichertes säuglingsnährpräparat
|
|
EP1119625B1
(en)
|
1998-10-07 |
2005-06-29 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
US6211144B1
(en)
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
|
DK1121145T3
(da)
|
1998-10-16 |
2002-08-12 |
Novo Nordisk As |
Insulinpræparater til indgivelse via lungerne, som indeholder mentol
|
|
UA65636C2
(uk)
|
1998-10-16 |
2004-04-15 |
Ново Нордіск А/С |
Стабільні концентровані препарати інсуліну для доставки через легені
|
|
EP1131089B1
(en)
|
1998-11-18 |
2004-02-18 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
|
US6489292B1
(en)
|
1998-11-18 |
2002-12-03 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
|
US6902744B1
(en)
|
1999-01-14 |
2005-06-07 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist formulations and methods of administration thereof
|
|
DE19908041A1
(de)
|
1999-02-24 |
2000-08-31 |
Hoecker Hartwig |
Kovalent verbrückte Insulindimere
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
JP2007204498A
(ja)
|
1999-03-01 |
2007-08-16 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
US6227819B1
(en)
|
1999-03-29 |
2001-05-08 |
Walbro Corporation |
Fuel pumping assembly
|
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
|
CA2372214A1
(en)
|
1999-04-30 |
2000-11-09 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
BR0010750A
(pt)
|
1999-05-17 |
2002-02-26 |
Conjuchem Inc |
Peptìdeos insulinotrópicos de longa duração
|
|
US6485706B1
(en)
|
1999-06-04 |
2002-11-26 |
Delrx Pharmaceutical Corp. |
Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
WO2001000223A2
(en)
|
1999-06-25 |
2001-01-04 |
Minimed Inc. |
Multiple agent diabetes therapy
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
DE19930631A1
(de)
|
1999-07-02 |
2001-01-11 |
Clemens Micheler |
Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
AU7984200A
(en)
|
1999-09-21 |
2001-04-24 |
Skyepharma Canada Inc. |
Surface modified particulate compositions of biologically active substances
|
|
DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
|
CZ20021186A3
(cs)
|
1999-10-04 |
2002-11-13 |
Chiron Corporation |
Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
|
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
|
BR0015294A
(pt)
|
1999-11-03 |
2003-07-15 |
Bristol Myers Squibb Co |
Método para tratamento da diabetes
|
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
|
EP1523993A1
(en)
|
1999-12-16 |
2005-04-20 |
Eli Lilly & Company |
Polypeptide compositions with improved stability
|
|
CN1409640A
(zh)
|
1999-12-16 |
2003-04-09 |
伊莱利利公司 |
稳定性改善的多肽组合物
|
|
US20010012829A1
(en)
|
2000-01-11 |
2001-08-09 |
Keith Anderson |
Transepithelial delivery GLP-1 derivatives
|
|
WO2001051071A2
(en)
|
2000-01-11 |
2001-07-19 |
Novo Nordisk A/S |
Transepithelial delivery of glp-1 derivatives
|
|
US6734162B2
(en)
|
2000-01-24 |
2004-05-11 |
Minimed Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
|
AU2001264789A1
(en)
|
2000-06-08 |
2001-12-17 |
Eli Lilly And Company |
Protein powder for pulmonary delivery
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
EP1970072A1
(en)
|
2000-09-18 |
2008-09-17 |
Sanos Bioscience A/S |
Use of GLP-2 peptides for the treatment of hyperparathyroidism
|
|
KR100508695B1
(ko)
|
2001-02-13 |
2005-08-17 |
한국과학기술연구원 |
인슐린의 경구투여용 제형과 그의 제조방법
|
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
|
DE10108100A1
(de)
|
2001-02-20 |
2002-08-29 |
Aventis Pharma Gmbh |
Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
|
|
DE10108211A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
|
|
DE10108212A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
|
|
WO2002067969A2
(en)
|
2001-02-21 |
2002-09-06 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
|
US20020177151A1
(en)
|
2001-02-26 |
2002-11-28 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of metabolic disorders, including obesity and diabetes
|
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
|
DE60233722D1
(de)
|
2001-04-02 |
2009-10-29 |
Novo Nordisk As |
Insulinvorstufen und verfahren zu deren herstellung
|
|
CN1160122C
(zh)
|
2001-04-20 |
2004-08-04 |
清华大学 |
一种制备口服胰岛素油相制剂的方法
|
|
US20030026872A1
(en)
|
2001-05-11 |
2003-02-06 |
The Procter & Gamble Co. |
Compositions having enhanced aqueous solubility and methods of their preparation
|
|
AU2002318159A1
(en)
|
2001-06-29 |
2003-03-03 |
The Regents Of The University Of California |
Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
|
|
FR2827604B1
(fr)
|
2001-07-17 |
2003-09-19 |
Sanofi Synthelabo |
Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
|
|
ATE408414T1
(de)
|
2001-07-31 |
2008-10-15 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
|
EP1432430A4
(en)
|
2001-08-28 |
2006-05-10 |
Lilly Co Eli |
PREMIXTURES OF GLP-1 AND BASALINSULIN
|
|
WO2003035028A1
(en)
|
2001-10-19 |
2003-05-01 |
Nektar Therapeutics |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
|
US20050013867A1
(en)
|
2001-10-19 |
2005-01-20 |
Lehrman S. Russ |
Use of proton sequestering agents in drug formulations
|
|
DE60236014D1
(de)
|
2001-11-19 |
2010-05-27 |
Novo Nordisk As |
Verfahren zur herstellung von insulinverbindungen
|
|
WO2003053363A2
(en)
|
2001-12-19 |
2003-07-03 |
Millennium Pharmaceuticals, Inc. |
Human diacylglycerol acyltransferase 2 (dgat2) family members and uses therefor
|
|
CZ2004710A3
(cs)
|
2001-12-20 |
2005-02-16 |
Eli Lilly And Company |
Inzulínová sloučenina s protrahovaným účinkem
|
|
EP1458408B1
(en)
|
2001-12-21 |
2009-04-15 |
Novo Nordisk Health Care AG |
Liquid composition of factor vii polypeptides
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
WO2003066084A1
(en)
|
2002-02-07 |
2003-08-14 |
Novo Nordisk A/S |
Use of glp-1 compound for treatment of critically ill patients
|
|
US20100069293A1
(en)
|
2002-02-27 |
2010-03-18 |
Pharmain Corporation |
Polymeric carrier compositions for delivery of active agents, methods of making and using the same
|
|
TWI351278B
(en)
|
2002-03-01 |
2011-11-01 |
Nisshin Pharma Inc |
Agent for preventing and treating of liver disease
|
|
WO2003094951A1
(en)
|
2002-05-07 |
2003-11-20 |
Novo Nordisk A/S |
Soluble formulations comprising insulin aspart and insulin detemir
|
|
JP5599543B2
(ja)
|
2002-05-07 |
2014-10-01 |
ノヴォ ノルディスク アー／エス |
単量体インスリン及びアシル化インスリンを含む可溶性製剤
|
|
US7115563B2
(en)
|
2002-05-29 |
2006-10-03 |
Insignion Holding Limited |
Composition and its therapeutic use
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
WO2004005342A1
(en)
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
|
DE10235168A1
(de)
|
2002-08-01 |
2004-02-12 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Reinigung von Preproinsulin
|
|
EP2384750A1
(en)
|
2002-09-27 |
2011-11-09 |
Martek Biosciences Corporation |
Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
|
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
DK1583541T3
(da)
|
2002-11-20 |
2011-04-11 |
Neuronova Ab |
Forbindelser og fremgangsmåder til at øge neurogenese
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
CN1413582A
(zh)
|
2002-11-29 |
2003-04-30 |
贵州圣济堂制药有限公司 |
盐酸二甲双胍肠溶片及其制备方法
|
|
WO2004050115A2
(en)
|
2002-12-03 |
2004-06-17 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
|
GB0309154D0
(en)
|
2003-01-14 |
2003-05-28 |
Aventis Pharma Inc |
Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
|
|
GB0304822D0
(en)
|
2003-03-03 |
2003-04-09 |
Dca Internat Ltd |
Improvements in and relating to a pen-type injector
|
|
BRPI0408105A
(pt)
|
2003-03-04 |
2006-03-01 |
Thetechnology Dev Company Ltd |
sistema de distribuição para droga e terapia celular
|
|
JP2007523842A
(ja)
|
2003-03-11 |
2007-08-23 |
ノボ ノルディスク アクティーゼルスカブ |
酸安定化されたインスリンを含有する薬学的製剤
|
|
US20040186046A1
(en)
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
|
EP1620465A2
(en)
|
2003-04-29 |
2006-02-01 |
Eli Lilly And Company |
Insulin analogs having protracted time action
|
|
EP1633390B1
(en)
|
2003-06-03 |
2012-01-18 |
Novo Nordisk A/S |
Stabilized pharmaceutical glp-1 peptide compositions
|
|
DE10325567B4
(de)
|
2003-06-05 |
2008-03-13 |
Mavig Gmbh |
Strahlenschutzanordnung mit separierbarer Umhüllung
|
|
CA2542372A1
(en)
|
2003-08-29 |
2005-03-10 |
Centocor, Inc. |
Method of promoting graft survival with anti-tissue factor antibodies
|
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
WO2005023291A2
(en)
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Use of glp1-agonists in the treatment of patients with type i diabetes
|
|
EP1667724A2
(en)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
ES2373660T3
(es)
|
2003-11-13 |
2012-02-07 |
Novo Nordisk A/S |
Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
WO2005048950A2
(en)
|
2003-11-17 |
2005-06-02 |
Biomune, Inc. |
Tumor and infectious disease therapeutic compositions
|
|
DE602004029496D1
(de)
|
2003-12-22 |
2010-11-18 |
Novo Nordisk As |
Offbehälter zur lagerung von pharmazeutischen flüssigkeiten
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
US7192919B2
(en)
|
2004-01-07 |
2007-03-20 |
Stelios Tzannis |
Sustained release compositions for delivery of pharmaceutical proteins
|
|
US20070027063A1
(en)
|
2004-01-12 |
2007-02-01 |
Mannkind Corporation |
Method of preserving the function of insulin-producing cells
|
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
|
US20070135338A1
(en)
|
2004-03-31 |
2007-06-14 |
Karyn O'neil |
Human GLP-1 mimetibodies, compositions, methods and uses
|
|
AU2005245240B2
(en)
|
2004-05-20 |
2010-04-29 |
Scimar Ltd. |
Use of drug combinations for treating insulin resistance
|
|
CA2567309A1
(en)
|
2004-06-01 |
2005-12-15 |
Ares Trading S.A. |
Method of stabilizing proteins
|
|
US8071624B2
(en)
|
2004-06-24 |
2011-12-06 |
Incyte Corporation |
N-substituted piperidines and their use as pharmaceuticals
|
|
WO2006000567A2
(en)
|
2004-06-28 |
2006-01-05 |
Novo Nordisk A/S |
Use of glp-1 receptor agonists and / or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i i and impaired pancreatic beta-cell function
|
|
WO2006091231A2
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
ES2309785T3
(es)
|
2004-08-13 |
2008-12-16 |
F. Hoffmann-La Roche Ag |
Modificacion c-terminal de polipeptidos.
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
US20060073213A1
(en)
|
2004-09-15 |
2006-04-06 |
Hotamisligil Gokhan S |
Reducing ER stress in the treatment of obesity and diabetes
|
|
JP2008513384A
(ja)
|
2004-09-17 |
2008-05-01 |
ノボ ノルディスク アクティーゼルスカブ |
インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物
|
|
JP2006137678A
(ja)
|
2004-11-10 |
2006-06-01 |
Shionogi & Co Ltd |
インターロイキン−２組成物
|
|
MX2007005521A
(es)
|
2004-11-12 |
2007-05-18 |
Novo Nordisk As |
Formulaciones estables de peptidos insulinotropicos.
|
|
WO2006051103A2
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
DE102004058306A1
(de)
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
|
SE0402976L
(sv)
|
2004-12-03 |
2006-06-04 |
Mederio Ag |
Medicinsk produkt
|
|
US20070128193A1
(en)
|
2004-12-22 |
2007-06-07 |
O'neil Karyn T |
GLP-1 agonists, compositions, methods and uses
|
|
US7879361B2
(en)
|
2005-01-04 |
2011-02-01 |
Gp Medical, Inc. |
Nanoparticles for drug delivery
|
|
US20090142338A1
(en)
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
|
US20080200383A1
(en)
|
2005-04-08 |
2008-08-21 |
Amylin Pharmaceuticals, Inc. |
Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
|
|
US8097584B2
(en)
|
2005-05-25 |
2012-01-17 |
Novo Nordisk A/S |
Stabilized formulations of insulin that comprise ethylenediamine
|
|
EP1888031B1
(en)
|
2005-06-06 |
2013-01-23 |
Camurus Ab |
Glp-1 analogue formulations
|
|
EP1948161B1
(en)
|
2005-06-27 |
2012-01-04 |
Newtree Co., Ltd. |
Method for preventing and treating conditions mediated by ppar using macelignan
|
|
EP1915334A2
(en)
|
2005-07-07 |
2008-04-30 |
Aditech Pharma AB |
Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
|
|
PL1971362T3
(pl)
|
2005-08-19 |
2015-05-29 |
Amylin Pharmaceuticals Llc |
Eksendyna do leczenia cukrzycy i zmniejszania masy ciała
|
|
EP1937297A2
(en)
|
2005-09-08 |
2008-07-02 |
Gastrotech Pharma A/S |
Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
|
|
AU2006291780B2
(en)
|
2005-09-14 |
2011-12-08 |
F. Hoffmann-La Roche Ag |
Cleavage of precursors of insulins by a variant of trypsin
|
|
EP1928499B1
(en)
|
2005-09-20 |
2011-06-29 |
Novartis AG |
Use of a dpp-iv inhibitor to reduce hypoglycemic events
|
|
WO2007038540A1
(en)
|
2005-09-26 |
2007-04-05 |
Medtronic, Inc. |
Prosthetic cardiac and venous valves
|
|
DE102005046113A1
(de)
|
2005-09-27 |
2007-03-29 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
|
|
KR101105871B1
(ko)
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
|
US8084420B2
(en)
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
|
WO2007044867A2
(en)
|
2005-10-11 |
2007-04-19 |
Huntington Medical Research Institutes |
Imaging agents and methods of use thereof
|
|
RU2395218C2
(ru)
|
2005-10-24 |
2010-07-27 |
Нестек С.А. |
Композиция пищевых волокон для профилактики или лечения заболеваний пищеварительной системы и композиция пищевых волокон, эффективная при лечении холеры
|
|
CN101309668A
(zh)
|
2005-11-30 |
2008-11-19 |
健乐克斯医药公司 |
经口吸收的药物制剂和用药方法
|
|
US20100029558A1
(en)
|
2005-12-06 |
2010-02-04 |
Bristow Cynthia L |
Alpha1 proteinase inhibitor peptides methods and use
|
|
EP2364735A3
(en)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Branched PEG conjugates of GLP-1
|
|
EP2913056A1
(en)
|
2006-01-05 |
2015-09-02 |
The University of Utah Research Foundation |
Methods and compositions related to improving properties of pharmacological agents targeting nervous system
|
|
WO2007081824A2
(en)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
|
US20090324701A1
(en)
|
2006-01-20 |
2009-12-31 |
Diamedica, Inc. |
Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
|
|
US20070191271A1
(en)
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
|
WO2007095288A2
(en)
|
2006-02-13 |
2007-08-23 |
Nektar Therapeutics |
Methionine-containing protein or peptide compositions and methods of making and using
|
|
WO2007098479A2
(en)
|
2006-02-21 |
2007-08-30 |
University Of Medicine And Dentistry Of New Jersey |
Localized insulin delivery for bone healing
|
|
EP1996224B1
(en)
|
2006-03-15 |
2012-11-07 |
Novo Nordisk A/S |
Mixtures of amylin and insulin
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
JP2009532422A
(ja)
|
2006-04-03 |
2009-09-10 |
ノボ・ノルデイスク・エー／エス |
Ｇｌｐ−１ペプチドアゴニスト
|
|
CN101454019A
(zh)
|
2006-04-12 |
2009-06-10 |
百达尔公司 |
速效和长效胰岛素联合制剂
|
|
MX2008013168A
(es)
|
2006-04-13 |
2008-10-27 |
Sod Conseils Rech Applic |
Composiciones faramaceuticas del peptido 1 similar al glucagon humano, exendina-4 y análogos de los mismos.
|
|
US20090099064A1
(en)
|
2006-06-08 |
2009-04-16 |
Diabecore Medical Inc., |
Derivatized insulin oligomers
|
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
|
JP2009544716A
(ja)
|
2006-07-27 |
2009-12-17 |
ノバルティス アクチエンゲゼルシャフト |
肺送達のためのインスリン含有エアロゾル化可能製剤
|
|
WO2008021560A2
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
|
WO2008023050A1
(en)
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
WO2008028914A1
(en)
|
2006-09-07 |
2008-03-13 |
Nycomed Gmbh |
Combination treatment for diabetes mellitus
|
|
RU2524150C2
(ru)
|
2006-09-22 |
2014-07-27 |
Ново Нордиск А/С |
Аналоги инсулина, устойчивые к протеазам
|
|
WO2008124522A2
(en)
|
2007-04-04 |
2008-10-16 |
Biodel, Inc. |
Amylin formulations
|
|
WO2008133908A2
(en)
|
2007-04-23 |
2008-11-06 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
WO2008145323A1
(en)
|
2007-05-31 |
2008-12-04 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for interferons
|
|
WO2008151737A1
(de)
|
2007-06-14 |
2008-12-18 |
Sanofi-Aventis Deutschland Gmbh |
Zweikammerkarpule
|
|
DK2167169T4
(en)
|
2007-06-14 |
2016-05-30 |
Sanofi Aventis Deutschland |
Tokammerkarpule with accessories
|
|
EP2173407B1
(en)
|
2007-07-02 |
2020-02-19 |
Roche Diabetes Care GmbH |
A device for drug delivery
|
|
US20090324609A1
(en)
|
2007-08-09 |
2009-12-31 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
JP5710253B2
(ja)
|
2007-08-13 |
2015-04-30 |
ノボ・ノルデイスク・エー／エス |
速効型インスリンアナログ
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
GB0717388D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
|
|
GB0717399D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
|
|
AU2008310076A1
(en)
|
2007-09-11 |
2009-04-16 |
Mondobiotech Laboratories Ag |
CGRP as a therapeutic agent
|
|
US20090104210A1
(en)
|
2007-10-17 |
2009-04-23 |
Tota Michael R |
Peptide compounds for treating obesity and insulin resistance
|
|
BRPI0818324B8
(pt)
|
2007-11-01 |
2021-05-25 |
Merck Serono Sa |
formulação líquida contendo hormônio luteinizante (lh) ou uma variante do mesmo, seu uso, sua forma de apresentação, processo para a sua preparação e composição farmacêutica
|
|
EP2217621B1
(en)
|
2007-11-08 |
2015-04-22 |
Novo Nordisk A/S |
Insulin derivative
|
|
BRPI0820535B8
(pt)
|
2007-11-16 |
2021-05-25 |
Novo Nordisk As |
composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
JP2011506442A
(ja)
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
|
EP2234644B1
(en)
|
2008-01-04 |
2013-07-31 |
Biodel, Inc. |
Insulin formulations for insulin release as a function of tissue glucose levels
|
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
JP5695909B2
(ja)
|
2008-01-09 |
2015-04-08 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
|
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
MY152979A
(en)
|
2008-01-09 |
2014-12-15 |
Sanofi Aventis Deutschland |
Novel insulin derivatives having an extremely delayed time-action profile
|
|
NZ586588A
(en)
|
2008-02-08 |
2012-10-26 |
Biogenerix Ag |
Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
|
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
RU2495131C2
(ru)
|
2008-02-19 |
2013-10-10 |
Байокон Лимитид |
Способ получения рекомбинантного инсулина гларгина
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
JP2011523052A
(ja)
|
2008-05-23 |
2011-08-04 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
Ｇｌｐ−１受容体アゴニスト・バイオアッセイ
|
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
|
CN102131516B
(zh)
|
2008-06-27 |
2016-03-16 |
杜克大学 |
包含弹性蛋白样肽的治疗剂
|
|
CA2735289A1
(en)
|
2008-08-30 |
2010-03-04 |
Sanofi-Aventis Deutschland Gmbh |
Cartridge and needle system therefor
|
|
WO2010028055A1
(en)
|
2008-09-02 |
2010-03-11 |
Biodel, Inc. |
Insulin with a basal release profile
|
|
CN103599541A
(zh)
|
2008-09-10 |
2014-02-26 |
弗·哈夫曼-拉罗切有限公司 |
用于防止蛋白质氧化降解的组合物和方法
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN102281865B
(zh)
|
2008-10-15 |
2017-04-05 |
精达制药公司 |
高浓缩药物颗粒、制剂、混悬剂及其应用
|
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
RS59913B1
(sr)
|
2008-10-17 |
2020-03-31 |
Sanofi Aventis Deutschland |
Kombinacija insulina i glp-1-agonista
|
|
JP4959005B2
(ja)
|
2008-10-30 |
2012-06-20 |
ノボ・ノルデイスク・エー／エス |
毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
|
|
JP2009091363A
(ja)
|
2008-11-21 |
2009-04-30 |
Asahi Kasei Pharma Kk |
Ｐｔｈの安定化水溶液注射剤
|
|
JP5677321B2
(ja)
|
2009-02-04 |
2015-02-25 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
血糖コントロール用の情報を提供するための医療デバイス及び方法
|
|
AU2010212823B2
(en)
|
2009-02-13 |
2016-01-28 |
Boehringer Ingelheim International Gmbh |
Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
|
EP2435061A4
(en)
|
2009-05-28 |
2013-03-27 |
Amylin Pharmaceuticals Inc |
DAMPING GLP-1 RECEPTOR AGONIST COMPOUNDS
|
|
CN102596175A
(zh)
|
2009-07-06 |
2012-07-18 |
赛诺菲-安万特德国有限公司 |
含有甲硫氨酸的水性胰岛素制备物
|
|
US20120241356A1
(en)
|
2009-07-06 |
2012-09-27 |
Sanofi-Aventis Deutschland Gmbh |
Heat- and vibration-stable insulin preparations
|
|
JP5675799B2
(ja)
|
2009-07-06 |
2015-02-25 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
遅効性インスリン製剤
|
|
US8709400B2
(en)
|
2009-07-27 |
2014-04-29 |
Washington University |
Inducement of organogenetic tolerance for pancreatic xenotransplant
|
|
NZ597964A
(en)
|
2009-07-31 |
2014-04-30 |
Sanofi Aventis Deutschland |
Long acting insulin composition
|
|
US8642548B2
(en)
|
2009-08-07 |
2014-02-04 |
Mannkind Corporation |
Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
US20110118180A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
PT3345593T
(pt)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
|
|
PL2324853T3
(pl)
|
2009-11-13 |
2016-01-29 |
Sanofi Aventis Deutschland |
Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
|
|
MY180661A
(en)
|
2009-11-13 |
2020-12-04 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
|
US20110118178A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
PL2329848T5
(pl)
|
2009-11-13 |
2019-12-31 |
Sanofi-Aventis Deutschland Gmbh |
Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2
|
|
WO2011075623A1
(en)
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
|
EP2460527A1
(en)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
PH12012501557A1
(en)
|
2010-02-22 |
2012-10-22 |
Univ Case Western Reserve |
Long-acting insulin analogue preparations in soluble and crystalline form
|
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
|
AR080884A1
(es)
|
2010-04-14 |
2012-05-16 |
Sanofi Aventis |
Conjugados de insulina-sirna
|
|
US8637458B2
(en)
|
2010-05-12 |
2014-01-28 |
Biodel Inc. |
Insulin with a stable basal release profile
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
WO2011144674A2
(en)
|
2010-05-20 |
2011-11-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
|
|
EP2389945A1
(en)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
|
WO2011160066A1
(en)
|
2010-06-17 |
2011-12-22 |
Regents Of The University Of Minnesota |
Production of insulin producing cells
|
|
US8532933B2
(en)
|
2010-06-18 |
2013-09-10 |
Roche Diagnostics Operations, Inc. |
Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
|
|
WO2012012352A2
(en)
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
PL2611458T3
(pl)
|
2010-08-30 |
2017-02-28 |
Sanofi-Aventis Deutschland Gmbh |
Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
|
|
PL2632478T3
(pl)
|
2010-10-27 |
2020-03-31 |
Novo Nordisk A/S |
Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu
|
|
WO2012065996A1
(en)
|
2010-11-15 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
|
|
WO2012066086A1
(en)
|
2010-11-17 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
|
|
WO2012080320A1
(en)
|
2010-12-14 |
2012-06-21 |
Novo Nordisk A/S |
Fast-acting insulin in combination with long-acting insulin
|
|
AU2012213435B2
(en)
|
2011-02-02 |
2017-03-30 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
|
TR201909840T4
(tr)
|
2011-03-11 |
2019-07-22 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antikorları ve kullanımları.
|
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
|
PT2707017E
(pt)
|
2011-05-13 |
2016-01-12 |
Sanofi Aventis Deutschland |
Lixisenatida e metformina para tratamento da diabetes tipo 2
|
|
WO2012177929A2
(en)
|
2011-06-24 |
2012-12-27 |
Amylin Pharmaceuticals, Inc. |
Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
|
|
AR087693A1
(es)
|
2011-08-29 |
2014-04-09 |
Sanofi Aventis Deutschland |
Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
WO2013050378A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
|
PL2763690T3
(pl)
|
2011-10-04 |
2016-04-29 |
Sanofi Aventis Deutschland |
Liksysenatyd do stosowania w leczeniu stenozy i/lub niedrożności w układzie przewodów trzustkowych
|
|
MX359329B
(es)
|
2011-10-28 |
2018-09-25 |
Sanofi Aventis Deutschland |
Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
GB201303771D0
(en)
|
2013-03-04 |
2013-04-17 |
Midatech Ltd |
Nanoparticles peptide compositions
|
|
JP6438944B2
(ja)
|
2013-06-17 |
2018-12-19 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリングラルギン／リキシセナチド固定比率製剤
|
|
TW201605489A
(zh)
|
2013-10-25 |
2016-02-16 |
賽諾菲公司 |
賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
|